Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases

Phase II trials have shown encouraging activity with ipilimumab plus fotemustine and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary analysis and four-year follow-up of the NIBIT-M2 study, the first phase III trial comparing these regimens to fotemustine in melanoma patients with brain metastases.